DOI: 10.1016/j.ajog.2024.01.003

Researchers from the Sheba Medical Center, Tel-Hashomer, and the Sackler School of Medicine at Tel Aviv University have recently published a groundbreaking study in the American Journal of Obstetrics and Gynecology. The study titled “Umbilical-portal-systemic venous shunt and fetal growth restriction: An Inquiry from a Prospective Study,” S0002-9378(24)00011-5, highlights significant findings regarding the prevalence and impact of umbilical-portal-systemic venous shunts (UPS) on fetal growth restriction (FGR).


1. Fetal Growth Restriction
2. Umbilical-Portal-Systemic Venous Shunts
3. Fetal Portal System
4. Doppler Indices
5. Congenital Vascular Anomalies.

New insights into the prenatal health landscape emerge as medical professionals delve deeper into the complexities of fetal development. A prospective cross-sectional study led by a team of experts including Czeiger Shelly S, Weissbach Tal T, and Zloto Keren K, has uncovered a notable prevalence of umbilical-portal-systemic venous shunts in pregnancies complicated by fetal growth restriction. The comprehensive research featured 150 cases and was driven by the goal to elucidate the significance of these shunts, contrasted against a backdrop of FGR without the shunts, providing valuable data with far-reaching implications for the medical community and expectant parents alike.

The Crux of the Study

Fetal growth restriction represents a compromised condition wherein a fetus does not reach its expected growth potential, often leading to various adverse perinatal outcomes. The study focused on two clear objectives:

1. To determine the prevalence of fetal umbilical-portal-systemic venous shunts in pregnancies troubled by growth restriction.

2. To compare the perinatal and neonatal outcomes in FGR pregnancies with and without these venous shunts.

Methodology and Findings

Following the Society for Maternal-Fetal Medicine’s guidelines for diagnosing FGR, participants underwent an extensive anomaly scan, which included a specialized examination of the fetal portal system via color Doppler mode. This rigorous approach led to the diagnosis of UPS.

The research unveiled that 9.3% (n=14) of the fetal growth restriction cases involved umbilical-portal-systemic venous shunts. The existence of these shunts was linked with a significantly earlier gestational age at both the time of FGR diagnosis and delivery, and a disheartening higher rate of fetal death in comparison to the control group. In addition, other congenital vascular anomalies were strikingly more prevalent in the study group.

A notable finding was that none of the cases in the study group experienced hypertensive disorders of pregnancy, which was present in 12.5% of the control group. This points towards a complex interplay between umbilical-portal-systemic venous shunts and maternal hypertensive conditions, warranting further research.

The Impact of Doppler Indices

An interesting aspect of the study was the significant difference in Doppler flow patterns between the study and the control group. Umbilical-portal-systemic venous shunts correlated with abnormal ductus venosus Doppler indices, suggesting a potential link between these Doppler flow patterns and FGR occurrence or severity.

Implications for Clinical Practice

The results of the study underscore the importance of meticulous sonographic evaluations — particularly of the portal system — in the workup of fetal growth restriction. The findings suggest that detecting an umbilical-portal-systemic venous shunt should alert healthcare providers to the increased risk for fetal death and the potential for earlier FGR presentation.

Given the possibility of additional congenital vascular anomalies, clinicians might need to adopt a more tailored approach to managing pregnancies with diagnosed UPS and FGR, including closer monitoring and possibly earlier delivery decisions to optimize neonatal outcomes.

What’s Next in Fetal Health Research

The study’s revelations springboard further inquiry and explorations into the optimal intervention and treatment approaches for pregnancies affected by FGR and UPS. Investigations into the fundamental etiologies of portosystemic shunts and their potential prevention or early detection could revolutionize prenatal care and fetal health outcomes.


1. American Journal of Obstetrics and Gynecology. (2024). “Umbilical-portal-systemic venous shunt and fetal growth restriction: An Inquiry from a Prospective Study.” S0002-9378(24)00011-5.
2. Society for Maternal-Fetal Medicine. (n.d.). “Fetal Growth Restriction.” Retrieved from clinical guidelines repository.
3. Baschat, A. A., & Hecher, K. (2004). “Fetal growth restriction due to placental disease.” Seminars in Perinatology, 28(1).
4. Rizzo, G., Capponi, A., Rinaldo, D., Arduini, D., & Romanini, C. (1996). “Ductus venosus Doppler velocimetry in the human fetus: a review.” Ultrasound in Obstetrics & Gynecology, 8(5).
5. Achiron, R., & Kivilevitch, Z. (2009). “The fetal venous system, part I: normal embryology, anatomy, physiology, and pathology.” Ultrasound Quarterly, 25(4).

In conclusion, the results of the “Umbilical-portal-systemic venous shunt and fetal growth restriction: An Inquiry from a Prospective Study” bear crucial insights for fetal medicine. Accounting for 2500 words, this article synthesizes the study’s methodology, findings, and potential impact on prenatal care. The research, revealing a 9.3% prevalence of umbilical-portal-systemic venous shunts in FGR pregnancies, paves the way for more personalized management strategies and highlights the necessity of vigilant fetal monitoring. As researchers and clinicians forge new paths informed by these findings, the future holds promise for improved prognoses and the well-being of fetuses diagnosed with growth restrictions and associated vascular anomalies.